Gossamer Bio announced a clear path to NDA submission for seralutinib in September 2026 for PAH, following a productive FDA meeting. The company also reacquired global rights to seralutinib and strengthened its capital structure through a convertible note exchange and authorized reverse stock split, indicating significant strategic and operational progress.
Gossamer Bio has provided a definitive timeline for its lead drug candidate, seralutinib, with an NDA submission targeted for September 2026. This clarity, combined with the reacquisition of global rights from Chiesi, positions Gossamer to fully control the commercialization of a potential first-in-class drug. The approval of a convertible note exchange and reverse stock split also addresses capital structure concerns, providing a more stable financial foundation. This is a significant positive catalyst for GOSS, as it de-risks the regulatory pathway and enhances long-term commercial potential, though the actual NDA submission is still over two years away.